Yan Ji

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Topics

Estrogen Receptor

Positive Breast Cancer

Top Venues

Clinical pharmacokinetics

CPT: pharmacometrics & systems pharmacology

Cancer chemotherapy and pharmacology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Yan Ji, Sherwin K B Sy
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy. Cancer chemotherapy and pharmacology (2024)
Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth, Serge Winter, Abhijit Chakraborty
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical pharmacokinetics 63 (2) (2024)
Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth, Serge Winter, Abhijit Chakraborty
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical pharmacokinetics (2024)
Yan Ji, Sherwin K B Sy
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy. Cancer chemotherapy and pharmacology 93 (4) (2024)
Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth, Serge Winter, Abhijit Chakraborty
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical pharmacokinetics 63 (2) (2024)
Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth, Serge Winter, Abhijit Chakraborty
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical pharmacokinetics 63 (2) (2024)
Yan Ji, Sherwin K B Sy
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy. Cancer chemotherapy and pharmacology 93 (4) (2024)
Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth, Serge Winter, Abhijit Chakraborty
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical pharmacokinetics 63 (2) (2024)
Yan Ji, Kumpal Madrasi, Deborah A Knee, Lore M Gruenbaum, Joshua F Apgar, John M Burke, Bruce Gomes
Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironment. CPT: pharmacometrics & systems pharmacology (2023)
Yan Ji, Kumpal Madrasi, Deborah A Knee, Lore M Gruenbaum, Joshua F Apgar, John M Burke, Bruce Gomes
Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironment. CPT: pharmacometrics & systems pharmacology 12 (3) (2023)
Yan Ji, Kumpal Madrasi, Deborah A Knee, Lore M Gruenbaum, Joshua F Apgar, John M Burke, Bruce Gomes
Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironment. CPT: pharmacometrics & systems pharmacology 12 (3) (2023)
Yan Ji, Vitaly Yartsev, Michelle Quinlan, Paolo Serra, Yingbo Wang, Abhijit Chakraborty, Michelle Miller
Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials. Clinical pharmacokinetics (2023)
Yan Ji, Claudio Calonder, Tiina Kirsilä, Alis Burciu, Matjaz Tisu, Yolandi Joubert, Nathalie Laurent, Eva Hua, Manmath Patekar, Anton Drollmann, Ralph Woessner
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System. Pharmaceutics 15 (9) (2023)
Yan Ji, Kumpal Madrasi, Deborah A Knee, Lore M Gruenbaum, Joshua F Apgar, John M Burke, Bruce Gomes
Quantitative Systems Pharmacology Model of GITR-mediated T cell dynamics in Tumor Microenvironment. CPT: pharmacometrics & systems pharmacology (2023)
Yan Ji, Eugene Tan, Thomas Hengelage, Michelle Quinlan, Bart S Hendriks
Exploratory food effect assessment in patients in early clinical development of oncology drugs. Clinical pharmacology and therapeutics (2023)
Yan Ji, Deborah Knee, Xinhui Chen, Anhthu Dang, Jennifer Mataraza, Babette Wolf, Sherwin K B Sy
Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose. Clinical and translational science 15 (9) (2022)
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi S El Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debasish Tripathy
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (5) (2022)
Komal Jhaveri, Dejan Juric, Yoon Sim Yap, Sara Cresta, Rachel M Layman, Fran Ois P Duhoux, Catherine Terret, Shunji Takahashi, Jens Huober, Nicole Kundamal, Qing Sheng, Alejandro Balbin, Yan Ji, Wei He, Adam Crystal, Serena De Vita, Curigliano Giuseppe
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (21) (2021)
Robert J Benschop, Chi-Kin Chow, Yu Tian, James Nelson, Barbra Barmettler, Shane Atwell, David Clawson, Qing Chai, Bryan E Jones, Jon Fitchett, Stacy Torgerson, Yan Ji, Holly Bina, Ningjie Hu, Mahmoud Ghanem, Joseph Manetta, Victor J Wroblewski, Jirong Lu, Barrett W Allan
Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. mAbs 11 (6) (2019)